When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
NEW YORK (Reuters Health) – Stereotactic body radiation therapy (SBRT) for early-stage non-small-cell lung cancer (NSCLC) results in “excellent 3-year local control and survival rates,” researchers report based…
NEW YORK (Reuters Health) – Although folate fortification of foods may reduce the rate of neural tube defects in target populations, new research from Chile suggests that it…
NEW YORK (Reuters Health) – In patients with newly diagnosed type 1 diabetes, high-dose immune ablation followed by autologous nonmyeloablative hematopoietic stem cell transplantation (HSCT) induces significant and…
NEW YORK (Reuters Health) – New research suggests that marijuana use may increase the risk of testicular germ cell tumors (TGCTs), primarily nonseminoma types. According to the report…
NEW YORK (Reuters Health) – Women with synchronous primary ovarian and endometrial cancers have better survival rates than women with single ovarian cancers do, according to a report…
ORLANDO (Reuters Health) – New findings, announced here during the annual meeting of the American College of Cardiology, show that rosuvastatin significantly reduces the risk of venous thromboembolism…
NEW YORK (Reuters Health) – Use of a high cut-off dialyzer can help patients with acute renal failure secondary to multiple myeloma become dialysis free, the results of…
NEW YORK (Reuters Health) For patients with epidermal growth factor (EGF) receptor-positive colorectal cancer and unresectable metastases, adding cetuximab to first-line treatment with irinotecan, fluorouracil, and leucovorin (FOLFIRI)…
NEW YORK (Reuters Health) – Annual ovarian cancer screening with transvaginal ultrasonography and CA 125 usually misses early-stage disease while it often results in unneeded surgeries, according to…
NEW YORK (Reuters Health) – For carefully selected patients with stage II to IVa laryngeal cancer, platinum-based chemotherapy may be sufficient to provide pathological complete response, results of…
